Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoid acid

Blood

Volumn 90, Issue 3, 1997, Pages 967-973

  Tobita, Tadasu ^b   Takeshita, Akihiro ^b   Kitamura, Kunio ^b   Ohnishi, Kazunori ^b   Yanagi, Mitsuaki ^b   Hiraoka, Akira ^b   Karasuno, Takahiro ^b   Takeuchi, Makoto ^b   Miyawaki, Shuuichi ^b   Ueda, Ryuzo ^b   Naoe, Tomoki ^b   Ohno, Ryuzo ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

RETINOIC ACID; TAMIBAROTENE;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CHEILITIS; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LEUKOCYTOSIS; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RETINOIC ACID SYNDROME; XEROSIS;

EID: 0030738326     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.3.967     Document Type: Article

References (45)

1. Hung ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, Gu LJ, Wang ZY: Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72:567, 1988
2. Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P, Degos L: All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 76:1704, 1990
3. Warrell RP Jr, Frankel SR, Miller WH Jr, Scheinberg DA, Itri LM, Hittelman WN, Vyas R, Andreeff M, Tafuri A, Jakubowski A, Gabrilove J, Gordon MS, Dmitrovsky E: Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 324:1385, 1991
4. Ohno R, Yoshida H, Fukutani H., Naoe T, Ohshima T, Kyo T, Endoh N, Fujimoto T, Kobayashi T, Hiraoka A, Mizoguchi H, Kodera Y, Suzuki H, Hirano M, Akiyama H, Aoki N, Shindo H, Yokomaku S, and the Leukemia Study Group of the Ministry of Health and Welfare: Multi-institutional study of all-trans retinoic acid as a differentiation therapy of refractory acute promyelocytic leukemia. Leukemia 7:1722, 1993
5. Kanamaru A, Takemoto Y, Tanimoto M, Murakami H, Asou N, Kobayashi T, Kuriyama K, Ohmoto E, Sakamaki H, Tsubaki K, Hiraoka A, Yamada O, Oh H, Saito K, Matsuda S, Minato K, Ueda T, Ohno R, and the Japan Adult Leukemia Study Group: All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Blood 85:1202, 1995
6. Warrell RP Jr, de Thé H, Wang ZY, Degos L: Acute promyelocytic leukemia. N Engl J Med 329:177, 1993
7. Degos L, Dombret H, Chomienne C, Daniel MT, Micléa JM, Chastang C, Castaigne S, Fenaux P: All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood 85:2643, 1995
8. Muindi J, Frankel SR, Miller WH Jr, Jakubowski A, Scheinberg DA, Young CW, Dmitrovsky E, Warrel RP Jr: Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: Implications for relapse and retinoid "resistance" in patients with acute promyelocytic leukemia. Blood 79:299, 1992
9. Delva L, Cornic M, Balitrand N, Guidez F, Micléa JM, Delmer A, Teillet F, Fenaux P, Castaigne S, Degos L, Chomienne C: Resistance to all-trans retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: Study of in vitro ATRA sensitivity and cellular retinoic acid binding protein levels in leukemic cells. Blood 82:2175, 1993
10. Cornic M, Delva L, Castaigne S, Lefebvre P, Balitrand N, Degos L, Chomienne C: In vitro all-trans retinoic acid (ATRA) sensitivity and cellular retinoic acid binding protein (CRABP) levels in relapse leukemic cells after remission induction by ATRA in acute promyelocytic leukemia. Leukemia 8:s16, 1994 (suppl 2)
11. Warrell RP Jr: Retinoid resistance in acute promytlocytic leukemia: New mechanisms, strategies, and implications. Blood 82:1949, 1993
12. Kegechica H, Kawachi E, Hashimoto Y, Himi T, Shudo K: Retinobenzoic acids. 1. Structure-activity relationships of aromatic amides with retinoidal activity. J Med Chem 31:2182, 1988
13. Hashimoto Y, Kagechica H, Kawachi E, Fukazawa H, Saito G, Shudo K: Correlation of differentiation-inducing activity of retinoids on human leukemia cell lines HL-60 and NB-4. J Can Res Clin Oncol 121:696, 1995
14. Takeshita A, Shibata Y, Shinjo K, Yanagi M, Tobita T, Ohnishi K, Miyawaki S, Shudo K, Ohno R: Successful treatment of relapse of acute promyelocytic leukemia with a new synthetic retinoid, Am 80. Ann Intern Med 124:893, 1996
15. Zelent A, Krust A, Petkovich M, Kastner P, Chambon P: Cloning of murine α and β retinoic acid receptors and novel receptor γ predominantly expressed in skin. Nature 339:714, 1989
16. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C: Proposal for the classification of the acute leukemias. Br J Haematol 33:451, 1976
17. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C: A variant form of hypergranular promyelocytic leukemia (M3). Ann Intern Med 92:261, 1980 (letter)
18. Kobayashi T, Miyawaki S, Tanimoto M, Kuriyama K, Murakami H, Yoshida M, Minami S, Minato K, Tsubaki K, Ohmoto E, Oh H, Jinnai I, Sakamaki H, Hiraoka A, Kanamaru A, Takahashi I, Saito K, Naoe T, Yamada O, Asou N, Kageyama S, Emi N, Matsuoka A, Tomonaga M, Saito H, Ueda R, Ohno R, for the Japan Adult Leukemia Study Group: Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. J Clin Oncol 14:204, 1996
19. Naoe T, Yoshida H, Kitaraura K, Chino M, Osumi, Ohno R: Delayed or insufficient restoration of PML and PML-PMLα subcellular localization after exposure in vitro to retinoic acids in all-trans retinoic acid-resistant APL cell. Leukemia 9:1610, 1995
20. Yoshida H, Kitamura K, Tanaka K, Omura S, Miyazaki T, Hachiya T, Ohno R, Naoe T: Accelerated degradation of PML-retinoic acid receptor α (PML-RARA) oncoprotein by all-trans retinoic acid in acute promyelocytic leukemia: Possible role of the proteasome pathway. Cancer Res 56:2945, 1996
21. Eardley AM, Heller G, Warrell RP Jr: Morbidity and costs of remission induction therapy with all-trans retinoic acid compared with standard chemotherapy in acute promyelocytic leukemia. Leukemia 8:934, 1994
22. Takeshita A, Sakamaki H, Miyawaki S, Kobayashi T, Kuriyama K, Yamada O, Oh H, Takenaka T, Asou N, Ohno R, and the Japan Adult Leukemia Study Group: Significant reduction of medical costs by differentiation therapy with all-trans retinoic acid during remission induction of newly diagnosed patients with acute promyelocytic leukemia. Cancer 76:602, 1995
23. Fenaux P, Castaigne S, Dombret H, Archimbaud E, Duarte M, Morel P, Lamy T, Tilly H, Guerci A, Maloisel F, Bordessoule D, Sadoun A, Tiberghien P, Fegueux N, Daniel MT, Chomienne C, Degos L: All-trans retinoic acid followed by intensive chemotherapy gives a high complete remission and may prolong remissions in newly diagnosed acute promyelocytic leukemia: A pilot study on 26 cases. Blood 80:2176, 1992
24. Warrell RP Jr, Maslak P, Eardley A, Heller G, Miller WH Jr, Frankel SR: Treatment of acute promyelocytic leukemia with all-trans retinoic acid: An update of the New York experience. Leukemia 8:s33, 1994 (suppl 2)
25. Yamada O, Hatake K, Tanimoto M, Ishiyama T, Ohno R, Shirakawa S, Horiuchi A, Tomonaga M, Ota K: Cooperative study of all-trans retinoic acid as a differentiation induction therapy of acute promyelocytic leukemia. Jpn J Cancer Chemother 21:1981, 1994
26. Ohno, R, Ohnishi K, Takeshita A, Tanimoto M, Murakami H, Kanamaru A, Asou N, Kobayashi T, Kuriyama K, Ohmoto E, Sakamaki H, Tsubaki K, Hiraoka A, Yamada O, Oh H, Furusawa S, Matsuda S, Naoe T: All-trans retinoic acid therapy in relapsed/refractory or newly diagnosed acute promyelocytic leukemia (APL) in Japan. Leukemia 8:s64, 1994 (suppl 3)
27. Chen ZX, Xue YQ, Zhang R, Tao RF, Xia XM, Li C, Wang W, Zu WY, Yao XZ, Ling BJ: A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood 78:1413, 1991
28. Roberts AB, Lamb LC, Sporn MB: Metabolism of all-trans retinoic acid in hamster liver microsomes: Oxidation of 4-hydroxyto 4-keto retinoic acid. Arch Biochem Biophys 199:374, 1980
29. Muindi, JF, Young CW: Lipid hydroperoxides greatly increase the rate of oxidative catabolism of all-trans retinoic acid by human cell culture microsomes genetically enriched in specified cytochrome P-450 isoforms. Cancer Res 53:1226, 1993
30. Kizaki M, Ueno H, Yamazoe Y, Shimada M, Takayama N, Muto A, Matsushita H, Nakajima H, Morikawa M, Koeffler HP, Ikeda Y: Mechanisms of retinoid resistance in leukemic cells: Possible role of cytochrome P450 and P-glycoprotein. Blood 87:725, 1996
31. Adamson PC, Bailey J, Pluda J, Poplack DG, Bauza S, Murphy RF, Yarchoran R, Balis FM: Pharmacokinetics of all-trans-retinoic acid administered on an intermittent schedule. J Clin Oncol 13:1238, 1995
32. Adamson PC, Boylan JF, Balis FM, Murphy RF, Godwin KA, Gudas LJ, Poplack DG: Time course of induction of metabolism of all-trans retinoic acid and the up-regulation of cellular retinoic acid-binding protein. Cancer Res 53:472, 1993
33. Boylan JF, Gudas LJ: The level of CRABP-I expression influences the amounts and types of all-trans-retinoic acid metabolites in F9 teratocarcinoma stem cells. J Biol Chem 267:21486, 1992
34. Robertson KA, Emami B, Collins SJ: Retinoic acid-resistant HL-60R cells harbor a point mutation in the retinoic acid receptor ligand-binding domain that confers dominant negative activity. Blood 80:1885, 1992
35. Dermime S, Grignani F, Clerici M, Nervi C, Sozzi G, Talamo GP, Marchesi E, Formelli F, Parmiani G, Pelicci PG, Gambacorti-Passerini C: Occurrence of resistance to retinoic acid in the acute promyelocytic leukemia cell line NB4 is associated with altered expression of the PML/RARα protein. Blood 82:1573, 1993
36. Miller WH Jr, Jakubowski A, Tong WP, Miller VA, Rigas JR, Benedetti F, Gill GM, Truglia JA, Ulm E, Shirley M, Warrel RP Jr: 9-cis retinoic acid induces complete remission but does not reverse clinically acquired retinoid resistance in acute promyelocytic leukemia. Blood 85:3021, 1995
37. Donovan M, Olofsson B, Gustafson AL, Dencker L, Eriksson U: The cellular retinoic acid binding proteins. Steroid Biochem Molec Biol 53:459, 1995
38. Rigas JR, Francis PA, Muindi JR, Kris MG, Huselton C, DeGrazia F, Orazem JP, Young CW, Warrel RP Jr: Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans-retinoic acid, and its modulation by ketoconazole. J. Natl Cancer Inst 85:1921, 1993
39. Schwartz EL, Hallam S, Gallagher RE, Wiernik PH: Inhibition of all-trans-retinoic acid metabolism by fluconazole in vitro and in patients with acute promyelocytic leukemia. Biochem Pharmacol 50:923, 1995
40. Koller E, Kreiger O, Kasparu H, Lutz D: Restoration of all-trans retinoic acid sensitivity by interferon in acute promyelocytic leukemia. Blood 79:299, 1992
41. Warrell RP Jr: Retinoid resistance. Lancet 341:126, 1993
42. Estey E, Thall PF, Mehta K, Rosenblum M, Brewer T Jr, Simmons V, Cabanillas F, Kurzrock R, Lopez-Berestein G: Alterations in tretinoin pharmacokinetics following administration of liposomal all-trans retinoic acid. Blood 87:3650, 1996
43. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 88:1052, 1996
44. Zhang P, Wang S, Hu L, Shi FD, Qiu FQ, Hong LJ, Han ZY, Yang HF, Song YZ, Liu YP, Zhou J, Jin ZJ: Treatment of acute promyelocytic leukemia with intravenous arsenic trioxide. Chin J Hematol 17:58, 1996
45. 3) in the treatment of APL: II Remission induction in relapsed patients and pharmacokinetics. Blood 88: p192a, 1996 (abstr, suppl 1)